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Supplementary Fig. 1. Cardiac function is unaltered by genetic targeting of the γ-secretase 
complex. Cardiac parameters were evaluated in Psenf/f;Psen2-/-;CreERT2/ERT2 mice by transthoracic 
echocardiography in B- and M-mode. Echochardiography was carried out before any treatment 
(Basal), after two injections (separated by 4 days) with vehicle or 4-OHT to induce Cre 
recombinase expression (TX), and after 15 days of Ang-II (ATII) subcutaneous osmotic pump 
implantation, as indicated. Graphs show ejection fraction (EF),fractional shortening (FS), and 
parameters measured to calculate left ventricular mass: internal diameter (LVID), posterior wall 
(LVPW), and interventricular septum thickness (IVS) measured at systole (s) and diastole (d). 




Supplementary Figure 2. Example to follow supplementary videos. Representative long-axis 
B-mode transthoracic echocardiography images of Psen1f/f;Psen2−/−;CreERT2/ERT2 mice  . Blue 
barsshow interventricular septum thickness (IVS), left ventricular internal diameter and left 
ventricular posterior wall (LVPW) measured at systole (s). For clarity papillary muscle is also 







Supplementary Fig. 3. Systolic pressure is unaltered by pharmacological targeting of the 
γ-secretase complex. Systolic blood pressure in vehicle- (n=9) or DBZ-treated (n=8) mice. The 
dotted black arrow indicates the time of Ang-II pump implantation and dotted grey arrows 
indicate the first day of four consecutive days of injections with the γ-secretase inhibitor (DBZ) 














Supplementary Fig. 4. DBZ impaired the expression of hypertrophic genes in NkL-TAg 
cells. qPCR analysis of the indicated genes in NkL-TAg cells treated with Ang-II and/or DBZ 
for 24h (n=3 per group). *** p<0.001; **p<0.01; *p<0.05. 
   
 
 
Supplementary Table 1. Demographic, hemodynamic, echocardiographic and treatments 
parameters in hypertensive male patients. SBP means systolic blood pressure; DBP, diastolic 
BP; LVMI, left ventricular mass index; RWT, relative wall thickness; LVH, LV hypertrophy; D, 
diuretics; BB, beta-blockers; AB, alpha-blockers; CCB, calcium channel blockers; ACEI, 
angiotensin converting enzyme inhibitors; ARA, angiotensin receptor antagonists. * The 
quantitative criteria to diagnose LVH either concentric (*) or eccentric (**) were the criteria 
recommended by Lang RM et al. J Am Soc Echocardiography 2005;18:1440-1463. SD, 
standard deviation. 
 
Age (y) SBP (mm Hg) DBP (mm Hg) LVMI (g/m2) RWT Treatment
68 143 87 103.58 0.40 D/ACEI-ARA
69 152 93 124.44 0.41 D/ACEI-ARA
73 145 91 128.50 0.39 D/BB-AB/CCB
70 140 92 94.09 0.38 D/CCB
70 155 95 94.55 0.40 BB-AB/CCB/ACEI-ARA
Mean ± SD 70 ± 1.87 147 ± 6.28 91.6 ± 2.97 109.03 ± 16.42 0.39 ± 0.01
66* 139 93 172.85 0.46 D/CCB/ACEI-ARA
73* 145 91 142.55 0.44 BB-AB/CCB
75* 151 90 154.56 0.45 D/CCB/ACEI-ARA
61* 149 99 141.70 0.43 D/ACEI-ARA
61** 148 88 140.86 0.41 D/BB-AB/CCB
Mean±SD 67.2  ± 6.57 146.4  ± 4.67 92.2 ± 4.21 144.9 ± 6.46 0.43 ± 0.01
LVH
non-LVH
